By reinforcing the concept of a durable, possibly neuroprotective effect, this study strengthened the rationale for GLP-1 RAs as disease-modifying candidates in Parkinson’s disease and supported the design of larger randomized trials. The gene discussed is GLP1R; the disease is Parkinson disease.